There are also a few cautions the FDA notes specific to this drug, including but not limited to: risk of pancreatitis hypoglycemia (low blood sugar) when used in conjunction with certain other drugs renal impairment or kidney failure acute gallbladder disease increased risk of thyroid C-cell tumors The FDA notes that patients who have had, or have family members who have had, medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use liraglutide, nor should individuals who have experienced prior serious hypersensitivity reaction to the drug
The oral route avoids injection risks entirely, which is a genuine safety advantage for many users, though it shares the broader uncertainty about long-term effects
A major trial, the EMPA-REG Outcome study, Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes enrolled patients with type 2 diabetes who were also at high risk of cardiovascular events such as strokes or heart attacks to take Empagliflozin and monitor if there were any beneficial effects in this group
GLP-1 medications should be used as part of a comprehensive weight management program that includes a reduced-calorie diet and increased physical activity.
Tirzepatide has been studied in two massive clinical trial programs, SURPASS for type 2 diabetes and SURMOUNT for weight management, collectively enrolling tens of thousands of participants across multiple countries and treatment durations
[DOI] [PubMed] [Google Scholar] 71.Filipova L., Lazurova Z., Fulop P., Lazurova I
